A type IV recombinant collagen with anti-thermal aging effects, its preparation method and application

By preparing and applying type IV recombinant collagen with anti-heat aging properties, the problem of skin aging caused by high temperature or infrared radiation was solved, the anti-heat aging ability of cells and the synthesis of collagen were improved, and the anti-aging effect of skin was achieved.

CN120988103BActive Publication Date: 2026-11-17GUANGDONG MARUBI BIOLOGICAL TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511178982.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-08-21
Publication Date
2026-11-17
Estimated Expiration
2045-08-21

AI Technical Summary

Technical Problem

Existing technologies lack effective methods to combat heat aging and address skin aging caused by high temperatures or infrared radiation, leading to skin structural damage and functional impairment, creating a vicious cycle.

Method used

A type IV recombinant collagen with anti-heat aging effects was prepared by designing a specific amino acid sequence (SEQ ID No. 1) and expressing it in Escherichia coli. High-purity collagen was obtained by fermentation culture and protein purification technology for use in formulations such as pharmaceuticals or cosmetics.

Benefits of technology

It significantly enhances the cells' ability to resist heat aging, slows down the rate of skin aging by increasing the expression of heat shock proteins, and promotes collagen synthesis under normal conditions, thereby enhancing skin firmness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120988103B_ABST
    Figure CN120988103B_ABST
Patent Text Reader

Abstract

This invention relates to a type IV recombinant collagen with anti-heat aging effects, its preparation method, and its applications. The amino acid sequence of the type IV recombinant collagen includes the sequence shown in SEQ ID No. 1. This invention provides a type IV recombinant collagen with anti-heat aging effects. Cells treated with this recombinant collagen showed a significant increase in the expression level of heat shock proteins after ultraviolet irradiation, indicating that the type IV recombinant collagen significantly enhances the cells' anti-heat aging ability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of bioengineering technology, and in particular to a type IV recombinant collagen with anti-thermal aging effects, its preparation method, and its application. Background Technology

[0002] Thermal aging is skin aging caused by prolonged exposure to high temperatures or infrared radiation (IR). The damage to the skin from high temperatures begins at the molecular level. When the ambient temperature exceeds 35°C, collagen and elastin fibers in the skin undergo irreversible denaturation under continuous thermal stress, leading to a loosening of the supporting structure and the appearance of signs of aging such as sagging and fine lines. Simultaneously, the dilation of capillaries caused by high temperatures exacerbates skin inflammation, prompting abnormal activity of melanocytes, resulting in age spots and uneven skin tone. More seriously, accelerated sweat evaporation damages the skin barrier function, causing a sharp drop in the moisture content of the stratum corneum. With the barrier function weakened, external irritants can more easily penetrate, creating a vicious cycle of "high temperature-inflammation-barrier damage."

[0003] Thermal energy is a form of energy that can be transferred in various ways; infrared radiation from sunlight or heat from the environment can be transferred to the skin. Humans are exposed to a large amount of heat daily, which is transferred to the body via infrared radiation, causing body temperature to briefly exceed 40 degrees Celsius. During this process, the skin tissue undergoes a significant oxidative stress response, affecting its structure and function. Because of the long wavelength of infrared radiation, many scholars believe that the thermal stimulation of infrared light not only damages the dermal tissue structure and skin elasticity but also damages fibroblasts, leading to rough skin and wrinkles.

[0004] Currently, there is more focus on areas such as skin aging and skin anti-oxidation, but little attention is paid to the impact of thermal aging on the skin. Therefore, there is an urgent need to discover a method that can combat skin thermal aging. Summary of the Invention

[0005] To address the aforementioned technical problems, this invention provides a type IV recombinant collagen with anti-thermal aging effects, its preparation method, and its application. The type IV recombinant collagen prepared by this invention can significantly enhance the anti-thermal aging ability of cells and slow down the skin aging rate.

[0006] To achieve this objective, the present invention adopts the following technical solution:

[0007] In a first aspect, the present invention provides a type IV recombinant collagen with anti-thermal aging effects, wherein the amino acid sequence of the type IV recombinant collagen includes the sequence shown in SEQ ID No. 1.

[0008] SEQ ID No. 1:

[0009] GFPGLPGQPGPPGLPVPGQAGAPGFPGERGEKGDRGFPGTSLPGPSGRDGLPGPPGSPGPPGQPGYTNGIVECQPGPPGDQGPPGIPGQPGFIGEIGEKGQKGESCLICDIDG YRGPPGPQGPPGEIGFPGQPGAKGDRGLPGRDGVAGVPGPQGTPGLIGQPGAKGEPGEFYFDLRLKGDKGDPGFPGQPGMPGRAGSPGRDGHPGLPGPKGSPGSVGLKGERGP PGFLVTRHSQTIDDPQCPSGTKILYHGYSLLYVQGNERAHGQDLGTAGSCLRKFSTMPFLFCNINNVCNFASRNDYSYWLSTPEPMPMSMAPITGENIRPFISRCAVCEAPAM VMAVHSQTIQIPPCPSGWSSLWIGYSFVMHTSAGAEGSGQALASPGSCLEEFRSAPFIECHGRGTCNYYANAYSFWLATIERSEMFKKPTPSTLKAGELRTHVSRCQVCMRRT.

[0010] In this invention, a type IV recombinant collagen with anti-thermal aging effects is provided. Cells treated with this recombinant collagen showed a significant increase in the expression of heat shock proteins after ultraviolet irradiation, indicating that the type IV recombinant collagen significantly enhances the cells' anti-thermal aging ability.

[0011] Secondly, the nucleic acid molecule encodes type IV recombinant collagen with the anti-thermal aging effect described in the first aspect.

[0012] Thirdly, the expression vector contains the nucleic acid molecule described in the second aspect; and after transfection / transduction / transformation of host cells, the expression vector causes the host cells to express the type IV recombinant collagen with the anti-thermal aging effect described in the first aspect.

[0013] Fourthly, the present invention provides a strain for producing type IV recombinant collagen with anti-heat aging effects, wherein the strain is a strain expressing type IV recombinant collagen with anti-heat aging effects as described in the first aspect.

[0014] Fifthly, the present invention provides a method for preparing type IV recombinant collagen with anti-heat aging effects according to the first aspect. The preparation method includes linking the nucleic acid sequence of type IV recombinant collagen with anti-heat aging effects to a vector and then transferring it into Escherichia coli, fermenting and culturing it with the transformed Escherichia coli, and then purifying the protein and purifying it using an instrument.

[0015] Preferably, the pH value of the fermentation culture is 6.8-7.2. For example, it can be 6.8, 6.9, 7, 7.1 or 7.2, etc.

[0016] Preferably, the initial dissolved oxygen concentration of the fermentation culture is 35-45%. For example, it can be 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, or 45%, etc.

[0017] Preferably, the aeration rate of the fermentation medium is 4-6 L / min. For example, it can be 4 L / min, 4.5 L / min, 5 L / min, 5.5 L / min, or 6 L / min, etc.

[0018] Preferably, the pressure of the fermentation medium is 0.03-0.07 MPa. For example, it can be 0.03 MPa, 0.04 MPa, 0.05 MPa, 0.06 MPa or 0.07 MPa, etc.

[0019] Preferably, the inoculum amount of Escherichia coli in the fermentation culture is 10-15%. For example, it can be 10%, 11%, 12%, 13%, 14%, or 15%, etc.

[0020] Preferably, the fermentation culture further includes a feeding operation.

[0021] Preferably, the feeding operation includes replenishing the culture medium until the dissolved oxygen concentration drops to 0% when the dissolved oxygen concentration rises back to 20%-30%. The 20%-30% can be, for example, 20%, 22%, 24%, 26%, 28%, or 30%.

[0022] Preferably, the fermentation medium used for fermentation culture is 2YT medium.

[0023] Preferably, the feeding medium is TYG medium.

[0024] Preferably, the protein purification method includes collecting the bacterial cells in the fermentation broth, rupturing them, centrifuging, collecting the supernatant, and filtering.

[0025] Preferably, the purification process includes nickel column purification.

[0026] In a sixth aspect, the present invention provides the use of the type IV recombinant collagen with anti-heat aging effects as described in the first aspect, the nucleic acid molecule as described in the second aspect, the expression vector as described in the third aspect, or the strain for producing type IV recombinant collagen with anti-heat aging effects as described in the fourth aspect in the preparation of a formulation with anti-heat aging effects.

[0027] The preparations include pharmaceuticals or cosmetics.

[0028] Preferably, the cosmetic includes any one or a combination of at least two of the following: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.

[0029] Compared with the prior art, the present invention has at least the following beneficial effects:

[0030] 1. This invention provides a type IV recombinant collagen with anti-thermal aging effects. Cells treated with this recombinant collagen showed a significant increase in the expression of heat shock proteins after ultraviolet irradiation, indicating that the type IV recombinant collagen significantly enhances the cells' anti-thermal aging ability.

[0031] 2. This invention provides a method for preparing type IV recombinant collagen with anti-heat aging effects. The method is simple to operate and can obtain type IV recombinant collagen with high purity, which is beneficial for large-scale production. Attached Figure Description

[0032] Figure 1 This is an electrophoresis image of the purified type IV recombinant collagen.

[0033] Figure 2 This is a comparison chart of HSP60 expression levels in different groups.

[0034] Figure 3 A comparison of HSP70 expression levels in different groups.

[0035] Figure 4 A comparison of COL1 expression levels in different groups.

[0036] Figure 5 A comparison of COL3 expression levels in different groups. Detailed Implementation

[0037] The technical solution of the present invention will be further described below with reference to the accompanying drawings and specific embodiments. However, the following examples are merely simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention is determined by the claims.

[0038] Example 1

[0039] This embodiment prepares type IV recombinant collagen with anti-thermal aging effects.

[0040] The nucleic acid sequence encoding the amino acid sequence of SEQ ID No. 1 was ligated into the pET-24 vector and then transformed into E. coli to obtain a prokaryotic expression vector.

[0041] (1) Seed liquid preparation

[0042] Transgenic Escherichia coli (BL21) preserved in glycerol was streaked onto solid LB medium containing 50 mg / mL kanamycin at a 1:250 ratio using an inoculation loop and incubated at 37°C for 16 h.

[0043] Select a single colony and inoculate it into 15 mL of LB medium (containing 1:1000 kan) at 37°C and 180 rpm for 8 h. Then inoculate it into 100 mL of LB medium (containing 1:1000 kan) and incubate overnight for 16 h. Finally, inoculate it into 400 mL of LB medium (containing 1:1000 kan) and incubate overnight for 16 h.

[0044] (2) Fermentation culture

[0045] Add 3L of 2YT culture medium (10g yeast extract, 16g peptone, and 4g sodium chloride dissolved in 1000mL deionized water, pH adjusted to 7.3, autoclaved at 121℃ for 25min) to a 7L fermenter. Calibrate the pH and dissolved oxygen meters. Connect the feed pump to TYG feed medium (140g peptone, 140g yeast extract, 5g magnesium sulfate, and 200g glycerol added to 1000mL deionized water, pH adjusted to 7.0, autoclaved at 121℃ for 20min). Connect the defoaming pump to the defoaming agent. After connecting the pipes, sterilize. Connect the acid / alkali pumps to 25% hydrochloric acid and ammonia water, respectively. Adjust the initial parameters of the fermenter to: pH 7, initial dissolved oxygen concentration 40%, stirring 500rpm, aeration 5L / min, and tank pressure 0.05MPa.

[0046] 3 mL of 50 mg / mL kanamycin was added to the fermenter using the flame inoculation method and left overnight. 400 mL of seed culture was then added using the flame inoculation method to start fermentation. The feed pump was not started immediately upon initiation. After 1 hour of fermentation, the dissolved oxygen (DO) value dropped below 40%, and even after stirring to the set upper limit, it could not be raised back to 40%, indicating that the cells had multiplied significantly.

[0047] After 4 hours of fermentation, the dissolved oxygen concentration (DO) began to rise from 0%. At this point, the feed pump was turned on, and when the system detected a DO concentration of 25%, TYG feed medium was added. After 15 minutes, the first 5 drops of TYG feed medium were added, and the DO value rapidly dropped to 0%. Approximately 10 minutes later, the DO concentration began to rise again, reaching 25%. Feed medium was then added again, and this cycle was repeated.

[0048] After 24.5 hours of fermentation, 1 M IPTG was added at a ratio of 1:1000 for induction. The feeding strategy remained the same as described above. Fermentation was then terminated after 30.5 hours.

[0049] (3) Protein purification

[0050] The fermentation broth was centrifuged using a tubular centrifuge to collect the bacterial cells. The collected cells were then resuspended in a "jack-of-all-trades buffer" (6.05 g tris(hydroxymethyl)aminomethane, 2.9 g sodium chloride, and 50 mL glycerol were added to 1000 mL of deionized water, and the pH was adjusted to 7.9 after mixing) at a ratio of 1 g / 10 mL. The cells were then homogenized using an autoclave and centrifuged at 12000 rpm for 30 min at 4 °C. The supernatant was collected, and the filtrate was filtered through a 0.45 μm ceramic membrane.

[0051] (4) Purification

[0052] Tris-HCl buffer containing 5 mM imidazole and 400 mM imidazole was prepared at pH 7.9. The buffers were automatically mixed using a protein purification system to obtain eluents of different imidazole concentrations. The eluents were loaded onto a nickel affinity chromatography column and eluted with 20 mM, 100 mM, 300 mM, and 400 mM imidazole, respectively. UV280 curves were observed, revealing a distinct single-protein absorption peak during elution with 300 mM imidazole. The corresponding eluents were collected.

[0053] The collected eluent was passed through a molecular sieve column in small amounts multiple times for desalting. The eluent was 20% 0.2M PBS buffer. The UV280 curve was observed, and the first protein peak to appear was the target protein that had been desalted.

[0054] The collected protein solution was mixed with 15% glycerol and 5% pentanediol and filtered again through a 0.45 μm membrane to complete the raw material preparation. Subsequent detection was performed using this raw material.

[0055] pass Figure 1 As can be seen, by using the above method, this invention successfully prepared type IV recombinant collagen with high purity and anti-heat aging effect. In this process, lane 1 is a 180kd marker, lane 2 is the filtrate, lane 3 is the flow-through buffer, lane 4 is a 20mM imidazole elution buffer, lane 5 is the first 100mM imidazole elution buffer, lane 6 is the second 100mM imidazole elution buffer, lane 7 is the first 300mM imidazole elution buffer, lane 8 is the second 300mM imidazole elution buffer, lane 9 is the third 300mM imidazole elution buffer, and lane 10 is a 400mM imidazole elution buffer.

[0056] Example 2

[0057] This embodiment conducts a heat aging test.

[0058] This embodiment uses human fibroblasts (BJ cells) for experiments, setting up three experimental groups: the experimental group, the aging group, and the commercially available product group, while also setting up a blank control group.

[0059] Senescent group: Human skin fibroblast BJ cell lines cultured in DMEM medium (Pronosai, PM150210) containing 10% fetal bovine serum (Sijiqing, 13011-8611) were grown to 70% abundance in 6-well plates. The medium was then replaced with PBS, and UV crosslinking was performed using a UV crosslinker at 15 mJ / cm². 2 The cells were irradiated with UVB, then the medium was replaced with one containing 2% fetal bovine serum. After starvation culture for 24 hours, the medium was replaced with one containing 0.01% distilled water and the treatment continued for another 24 hours.

[0060] Test group: Human skin fibroblast BJ cell lines cultured in DMEM medium containing 10% fetal bovine serum were grown to 70% abundance in 6-well plates. The medium was then replaced with PBS, and UV crosslinking was performed at 15 mJ / cm². 2 After UVB irradiation, the culture medium was replaced with one containing 2% fetal bovine serum and starved for 24 hours. Then, the culture medium was replaced with one containing 0.01% of the type IV recombinant collagen prepared in Example 1 and the treatment continued for another 24 hours.

[0061] Commercially available product group: Human skin fibroblast BJ cell lines cultured in DMEM medium containing 10% fetal bovine serum were grown to 70% abundance in 6-well plates. The medium was then replaced with PBS, and UV crosslinking was performed at 15 mJ / cm². 2 After UVB irradiation, the culture medium was replaced with one containing 2% fetal bovine serum and starved for 24 hours. Then, the medium was replaced with one containing 0.01% HydroCol-y recombinant collagen from Best Pharmaceuticals (Guangzhou) Co., Ltd. and the treatment continued for another 24 hours.

[0062] Blank group: Human skin fibroblast BJ cell lines cultured in DMEM medium containing 10% fetal bovine serum were grown to 70% abundance in 6-well plates, and then the medium was replaced with medium containing 2% fetal bovine serum. After starvation culture for 24 h, the medium was replaced with DMEM medium containing 0.01% PBS and the treatment continued for 24 h.

[0063] Some conjugated amino acid residues in recombinant type IV collagen absorb at 280–320 nm. The excited state generated by ultraviolet radiation can be converted into local heat energy via non-radiative transitions, resulting in an instantaneous temperature rise of approximately 5–10 °C in the peptide chain. Therefore, the ultraviolet crosslinker induces peptide chain breakage and oxidative crosslinking on the protein surface, similar to macroscopic thermal aging. In summary, irradiation using an ultraviolet crosslinker can be considered to simulate the macroscopic process of skin thermal aging.

[0064] Heat shock protein 60 (HSP60) is a mitochondrial chaperone protein that maintains protein folding and translocation within mitochondria. Heat stress and protein toxicity upregulate HSP60 and trigger the mitochondrial unfolded protein response.

[0065] Heat shock protein 70 (HSP70) is one of the fastest and most significant inducible molecules of heat shock. It is responsible for preventing protein aggregation, promoting the refolding or degradation of misfolded proteins, and can also inhibit the JNK / caspase pathway and reduce apoptosis.

[0066] Based on the positive significance of the two proteins' performance on protein homeostasis under thermal shock, the upregulation of their gene expression can serve as a biomarker for enhancing the cell's resistance to thermal aging under stress by adding the analyte.

[0067] RNA was extracted from cells using TRIzol reagent. After determining the RNA concentration, the mRNA was reverse transcribed into cDNA, which was then used as a template for quantitative real-time PCR to detect the synthesis and expression of the target molecule at the gene level. Each sample was tested three times independently, and the results are presented as mean ± standard deviation. RNA concentrations are shown in Table 1. Quantitative real-time PCR results are shown in Table 2.

[0068] Table 1

[0069]

[0070]

[0071] Table 2

[0072]

[0073] Table 3

[0074] project Expression level difference fold Expression features Aging group / blank control 0.195 Lower Experimental group / blank control 1.376 Upward Commercially available product group / blank control 0.525 Lower Experimental group / aging group 7.056 Upward

[0075] like Figure 2 As shown in Table 3, compared with the blank control group, UVB treatment significantly inhibited the synthesis level of heat shock protein 60, reducing it to 19.50% of the blank control. Compared with aging, treatment with 0.01% concentration of recombinant type IV collagen prepared in Example 1 significantly increased the synthesis of heat shock protein 60 to 137.6% of the blank control group, while commercially available products only increased the synthesis level to 52.5%. These results indicate that simulated thermal aging environments lead to a sharp decline in the expression of heat shock protein 60, significantly reducing its anti-thermal aging ability. However, recombinant type IV collagen can significantly recover the synthesis of heat shock protein 60, and its effect is superior to commercially available products.

[0076] Table 4

[0077]

[0078]

[0079] like Figure 3As shown in Table 4, compared with the blank control group, UVB treatment significantly inhibited the synthesis level of heat shock protein 70, reducing it to 20.9% of the blank control. Compared with aging, treatment with 0.01% concentration of recombinant type IV collagen prepared in Example 1 significantly increased the synthesis of heat shock protein 70 to 105.7% of the blank control group, while commercially available products only increased the synthesis level to 39.7%. These results indicate that simulated thermal aging environments lead to a sharp decline in the expression of heat shock protein 70, significantly reducing its anti-thermal aging ability. However, recombinant type IV collagen can significantly recover the synthesis of heat shock protein 70, and its effect is superior to that of commercially available products.

[0080] Example 3

[0081] This embodiment conducts a collagen-promoting experiment.

[0082] After the human skin fibroblast BJ cell line in the 6-well plates reached 70% abundance, the medium was replaced with medium containing 2% FBS and starved for 24 hours. Then, the medium was replaced with medium containing 0.05% of type IV recombinant collagen prepared in Example 1 and 0.1% of type IV recombinant collagen prepared in Example 1, and treated for 24 hours. RNA was extracted from the cells using TRIzol reagent, and after determining the RNA concentration, the mRNA was reverse transcribed into cDNA. This cDNA was then used as a template for quantitative real-time PCR to detect the synthesis and expression of the target molecule at the gene level. Each sample was tested three times independently, and the results are presented as mean ± standard deviation.

[0083] Table 5

[0084] Experimental group OD260 OD280 OD260 / OD280 RNA concentration (μg / μL) 0.05% Type IV Recombinant Collagen 0.1134 0.0607 1.8682 0.4536 0.1% Type IV recombinant collagen 0.1281 0.0657 1.9498 0.5124 Blank control group 0.1023 0.0565 1.8106 0.4092

[0085] Table 6

[0086]

[0087]

[0088] pass Figure 4 and Figure 5It can be seen that treatment of cells with 0.05% and 0.1% concentrations of recombinant type IV collagen significantly increased the synthesis level of type III collagen. RNA concentrations are shown in Table 5. The results of quantitative real-time PCR are shown in Table 6. Compared with the blank control, the gene synthesis of type III collagen significantly increased by 1.33 times after treatment with 0.05% recombinant type IV collagen, and significantly increased by 1.52 times after treatment with 0.1% recombinant type IV collagen. This demonstrates that under normal conditions, recombinant type IV collagen has the ability to promote the expression of type I and type III collagen, thus indicating its potential role in skin anti-wrinkle and firming.

[0089] In summary, this invention provides a type IV recombinant collagen with anti-thermal aging effects. Cells treated with this recombinant collagen showed a significant increase in the expression of heat shock proteins after ultraviolet irradiation, indicating that the type IV recombinant collagen significantly enhances the cells' anti-thermal aging ability.

[0090] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.

Claims

1. A type IV recombinant collagen with anti-heat aging effects, characterized in that, The amino acid sequence of the type IV recombinant collagen is as shown in SEQ ID No.

1.

2. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the type IV recombinant collagen with the anti-thermal aging effect described in claim 1.

3. An expression carrier, characterized in that, The expression vector contains the nucleic acid molecule of claim 2; and after transfection / transduction / transformation of host cells, the expression vector causes the host cells to express the type IV recombinant collagen with anti-thermal aging effects of claim 1.

4. A bacterial strain that produces type IV recombinant collagen with anti-heat aging effects, characterized in that, The strain is a type IV recombinant collagen strain expressing the anti-thermal aging effect described in claim 1.

5. A method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 1, characterized in that, The preparation method includes linking the nucleic acid sequence of type IV recombinant collagen with anti-heat aging effect to a vector and then transferring it into Escherichia coli. The transformed E. coli is then fermented and cultured, and the protein is purified and purified by machine to obtain the final product.

6. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The pH value of the fermentation culture is 6.8-7.

2.

7. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The initial dissolved oxygen concentration of the fermentation culture is 35%-45%.

8. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The aeration rate of the fermentation medium is 4-6 L / min.

9. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The pressure of the fermentation medium is 0.03-0.07 MPa.

10. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The inoculum size of Escherichia coli in the fermentation culture is 10-15%.

11. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The fermentation culture also includes a feeding operation.

12. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 11, characterized in that, The feeding operation includes replenishing the culture medium when the dissolved oxygen concentration rises to 20%-30% until the dissolved oxygen concentration drops to 0%.

13. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The fermentation medium used for the fermentation culture was 2YT medium.

14. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 12, characterized in that, The feeding medium is TYG medium.

15. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The protein purification method includes collecting the bacterial cells in the fermentation broth, rupturing them, centrifuging, collecting the supernatant, and filtering.

16. The method for preparing type IV recombinant collagen with anti-thermal aging effects according to claim 5, characterized in that, The purification process includes nickel column purification.

17. The use of a type IV recombinant collagen with anti-heat aging effects according to claim 1, the nucleic acid molecule according to claim 2, the expression vector according to claim 3, or the strain for producing type IV recombinant collagen with anti-heat aging effects according to claim 4 in the preparation of a formulation with anti-heat aging effects.

18. The application according to claim 17, characterized in that, The preparations include pharmaceuticals or cosmetics.

19. The application according to claim 18, characterized in that, The cosmetics include any one or a combination of at least two of the following: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.

Citation Information

Patent Citations

  • Recombinant human type 4 collagen as well as preparation method and application thereof

    CN117024572A

  • Recombinant IV type collagen as well as preparation method and application thereof

    CN119286901A